Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 3, Issue , 2016, Pages 103-109

  Weinstein, Galit ^a   Beiser, Alexa S ^a,b,c   Preis, Sarah R ^a,c   Courchesne, Paul ^a   Chouraki, Vincent ^a,b   Levy, Daniel ^a,d   Seshadri, Sudha ^a,b  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Dementia; Epidemiology; Plasma clusterin; Risk factors; Stroke

Indexed keywords

C REACTIVE PROTEIN; CLUSTERIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DEMENTIA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VERY ELDERLY;

EID: 84978536011     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2016.06.005     Document Type: Article

References (37)

1. Bettens K., Sleegers K., Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol 2013, 12:92-104.
2. Thambisetty M., Beason-Held L.L., An Y., Kraut M., Nalls M., Hernandez D.G., et al. Alzheimer Risk Variant CLU and Brain Function During Aging. Biol Psychiatry 2013, 73:399-405.
3. Ling I.F., Bhongsatiern J., Simpson J.F., Fardo D.W., Estus S. Genetics of clusterin isoform expression and Alzheimer's disease risk. PLoS One 2012, 7:e33923.
4. Schurmann B., Wiese B., Bickel H., Weyerer S., Riedel-Heller S.G., Pentzek M., et al. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis 2011, 25:421-424.
5. Xing Y.Y., Yu J.T., Cui W.Z., Zhong X.L., Wu Z.C., Zhang Q., et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. J Alzheimers Dis 2012, 29:515-519.
6. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010, 67:739-748.
7. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009, 61:89-104.
8. Wu Z.C., Yu J.T., Li Y., Tan L. Clusterin in Alzheimer's disease. Adv Clin Chem 2012, 56:155-173.
9. Yu J.T., Tan L. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol Neurobiol 2012, 45:314-326.
10. Schrijvers E.M., Koudstaal P.J., Hofman A., Breteler M.M. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305:1322-1326.
11. Mullan G.M., McEneny J., Fuchs M., McMaster C., Todd S., McGuinness B., et al. Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 2013, 10:973-978.
12. Song F., Poljak A., Crawford J., Kochan N.A., Wen W., Cameron B., et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 2012, 7:e34078.
13. Silajdzic E., Minthon L., Bjorkqvist M., Hansson O. No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS One 2012, 7:e50237.
14. Wilson M.R., Yerbury J.J., Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst 2008, 4:42-52.
15. Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., Dobson C.M., et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 2007, 21:2312-2322.
16. Desikan R.S., Thompson W.K., Holland D., Hess C.P., Brewer J.B., Zetterberg H., et al. The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol 2014, 71:180-187.
17. Won J.C., Park C.Y., Oh S.W., Lee E.S., Youn B.S., Kim M.S. Plasma clusterin (ApoJ) levels are associated with adiposity and systemic inflammation. PLoS One 2014, 9:e103351.
18. Gardener H., Wright C.B., Rundek T., Sacco R.L. Brain health and shared risk factors for dementia and stroke. Nat Rev Neurol 2015, 11:651-657.
19. Park S., Mathis K.W., Lee I.K. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord 2014, 15:45-53.
20. Feinleib M., Kannel W.B., Garrison R.J., McNamara P.M., Castelli W.P. The Framingham Offspring Study. Design and preliminary data. Prev Med 1975, 4:518-525.
21. Diagnostic and statistical manual of mental disorders: DSM-IV 1994, American Psychiatric Association, Washington, D.C. 4th ed.
22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
23. Elosua R., Ordovas J.M., Cupples L.A., Fox C.S., Polak J.F., Wolf P.A., et al. Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res 2004, 45:1868-1875.
24. IJsselstijn L., Dekker L.J., Koudstaal P.J., Hofman A., Sillevis Smitt P.A., Breteler M.M., et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J Proteome Res 2011, 10:2006-2010.
25. Thambisetty M., An Y., Kinsey A., Koka D., Saleem M., Guntert A., et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 2012, 59:212-217.
26. Deli M.A., Veszelka S., Csiszar B., Toth A., Kittel A., Csete M., et al. Protection of the blood-brain barrier by pentosan against amyloid-beta-induced toxicity. J Alzheimers Dis 2010, 22:777-794.
27. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
28. Pluta R. Role of ischemic blood-brain barrier on amyloid plaques development in Alzheimer's disease brain. Curr Neurovasc Res 2007, 4:121-129.
29. Matsubara E., Soto C., Governale S., Frangione B., Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996, 316:671-679.
30. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
31. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
32. Martorana A., Bulati M., Buffa S., Pellicano M., Caruso C., Candore G., et al. Immunosenescence, inflammation and Alzheimer's disease. Longev Healthspan 2012, 1:8.
33. Holmes C. Review: systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol 2013, 39:51-68.
34. Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015, 14:388-405.
35. Salminen A., Ojala J., Kauppinen A., Kaarniranta K., Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009, 87:181-194.
36. Eikelenboom P., Veerhuis R., van Exel E., Hoozemans J.J., Rozemuller A.J., van Gool W.A. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 2011, 8:142-150.
37. Bi B.T., Lin H.B., Cheng Y.F., Zhou H., Lin T., Zhang M.Z., et al. Promotion of beta-amyloid production by C-reactive protein and its implications in the early pathogenesis of Alzheimer's disease. Neurochem Int 2012, 60:257-266.